

Review Article

Open Access

Aging People with Viral Infection, Novel Strategies

Da Yong Lu*, Jin Yu Che and Hong Ying Wu

School of Life Sciences, Shanghai University, China

ABSTRACT

Human beings are medically easy to infect with dangerous bacteria and viruses. The risks for bacteria or viral-induced human morbidity and mortality is complex and multi-factorial. However, a long-term awareness that old people are more vulnerable to microbial infections than adulthood, especially like seasonal viruses spur more recently. This phenomenon may be attributed to different risk factors of physiological, pathological and therapeutic reasons. This article outlines this string of problems and tries to find answers from different clinical evidences and biomedical logics.

***Corresponding author**

Da Yong Lu, School of Life Sciences, Shanghai University, China.

Received: May 22, 2026; **Accepted:** May 27, 2026; **Published:** June 05, 2026**Keywords:** Viral Infection, Diagnosis, Physiology, Therapies**Introduction**

Human beings are medically easy to infect with dangerous bacteria and viruses. The risks for bacteria or viral-induced human morbidity and mortality is complex and multi-factorial. However, it is a long-term awareness that old people are more vulnerable to viral infections than adulthood, especially like seasonal viruses.

This phenomenon may be attributed to different pathways and risks of physiological, pathological and therapeutic disciplines and field. This article outlines this string of problems and tries to find answers from different clinical evidences and biomedical logics and sciences. Researches should be focused on disciplines of patient treatments and survivals.

Character

Microbial are widely distributed in Earths. Among the tremendous numbers of different types of bacteria and viruses, a lot of viruses are fatal to human beings [1-7]. Human beings are easy to infect with different viruses worldwide. The risk for viral-induced human morbidity and mortality is very high. However, it is easy to note that old people are more vulnerable to viral infections, especially risky viruses. The phenomenon may be caused by different physiological, pathological and therapeutic reasons.

BOX. Characters and features for viral infections in elders

More moderate or serious symptoms in old peoples
More underlying diseases that makes people vulnerable for disease progress
Difficult to virus identifications and diagnosis for a huge numbers of different viruses
Shortage of effective drugs or vaccines for different kinds of viruses, especially new emerging diseases

Scenarios for Old People

Old people are obviously more vulnerable to virus infections

and induce more number of human morbidity and mortality in the clinic. It is a long-standing phenomenon in medical histories. It is a common feature of super dangerous waiting for new breakthroughs.

Different symptoms (mild or severer) will cause old people in beds or deaths suddenly. New approaches should be made to invent many prevent and treatment measure to reduce many virus-induced morbidity and mortality.

Table: Major Pathological Pathways

Major pathogenesis	Main pathways
Immune Dysregulation	Function or Cell Number Declines
Recovery	Longer phase of Body Recovery
Nutrition	Poor Digestion and Ill Nutrition in Old Peoples
Vaccines	Most of Vaccine Functions have been Lost
Pharmacology	Low Efficacy and Large Toxicity for Different Drugs

New Approaches

Biomedical study for viral diagnosis and treatment in old people can be enormous and usefulness. They are occupied in different approaches;

Find ways of virus detection in low costs and easy to handle
Genetic and molecular study of viral infections [8-13].
Pathological and therapeutic information comparisons between old people and youths
Discover new techniques or drugs to treat infectious old patients [14-20].
Diagnostic and therapeutic transition [21-23].
Find effective vaccines for old people in epidemics or winter.
Others

Conclusion

Old people demand extensive care and special medical treatments. We should find ways to improve these kinds of biomedical study and make breakthroughs as early as possible.

References

1. Lu DY (2017) HIV/AIDS Treatments, Fight for a Cure. LAMBERT Academic Publishing.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, et al. (2020) A novel coronavirus from patients with pneumonia in China. *N Engl J Med* 382: 727-733.
3. Lu DY, Lu TR (2024) COVID-19 research, public health and biomedical basis. *Current Drug Therapy* 19: 367-375.
4. Zerbato V, Rossi B, Bella SD, Bartalucci C, Cerdaro M, et al. (2026) West Nile virus, epidemiology, prevention, clinical features, diagnosis, treatment, and open research questions. *Annals of Medicine* 58: 2615482.
5. Lu DY, Lu TR, Wu HY (2012) Avian flu, pathogenesis and therapy. *Anti-Infective Agents* 10: 124-129.
6. Hossain T, Cheyan FU, Iqbal H, Alam F, Syrmos N (2025) Situation report of clinical and climatic pattern changes in Dengue outbreaks in Bangladesh 2024-2025. *Journal of Current Health Science* 5: 231-240.
7. Lu DY, Wu HY, Yarla NS, Lu TR, Xu B, et al. (2019) Ebola therapeutic study and future trends. *Infect Disorder Drug Targets* 19: 17-29.
8. Lu DY, Ding J (2007) Sequencing the whole genome of infected human cells obtained from diseased patients-a proposed strategy for understanding and overcoming AIDS or other deadliest virus-infected diseases. *Medical Hypotheses* 68: 826-827.
9. Lu DY, Ding J (2007) AIDS and human genome studies, from a hypothesis to systematic approaches. *Med Hypotheses* 69: 695.
10. Lu DY, Lu TR (2025) Viral integration into human genome, potential approaches. *EC Microbiology* 21: 1-2.
11. Tang DY, Li BR, Xu TY, Hu RF, Tan DQ, et al. (2020) VISDB: a manually curated database of viral integration sites in the human genome. *Nucleic Acid Res* 48: 633-641.
12. Lu DY, Lu TR (2025) Possible solution for coronavirus diagnosis and treatment, viral integration into human genomes. *Journal of Lung, Pulmonary and Respiratory Research* 12: 49.
13. Lu DY, Lu TR (2025) Viral integration into human genome, hopes for breakthroughs. *Hospice & Palliative Medicine International Journal* 8: 90-91.
14. Lu DY, Wu HY, Yarla NS, Xu B, Ding J, et al. (2018) HAART in HIV/AIDS treatments, future trends. *Infectious Disorders-Drug Targets* 18: 15-22.
15. Subramaniam S, Savile JW, Feng F, Freiburger L (2025) Therapeutic antibodies for infectious diseases, recent past, present, and future. *Biochemistry* 64: 3487-3494.
16. Lu DY, Lu TR (2023) HIV/AIDS curability study, different approaches and drug combination. *Infectious Disorders-Drug Targets* 23: 170123212803.
17. Lu DY, Lu TR (2025) COVID-19 study: a new principle discovery. *Current Drug Therapy* 20: 450-457.
18. Zhao YN (2024) Advances in HIV research: mechanisms, transmission route, and emerging therapeutic strategies. *Highlights in Science, Engineering and Technology* 123: 505-509.
19. Naqvi IA, Tazvi SNZ (2020) The comprehensive appraisal of COVID-19: its clinical panorama from virology till management and beyond. *Coronavirus* 1: 57-72.
20. Rao DV, Dattatreya A, Dan MM, Sarangi T, Sasidhar K, et al. (2017) Translational approach in emerging infectious disease treatment: an update. *Biomedical Res* 28: 5678-5686.
21. Lu DY, Lu TR (2024) Covid-19 study, diagnostic and therapeutic transition. *Rec Advances in Anti-Infective Drug Discovery* 19: 21-35.
22. Lu DY (2025) COVID-19 conception advances, epidemics, pathology and therapeutics. *J Bacteria Mycol Open Access* 13: 135-139.
23. Lu DY (2025) COVID-19 knowledge and therapeutics, past, present and future. *J Bacteriology and Mycology: Open Access* 13: 110-114.

Copyright: ©2026 Da Yong Lu, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.